BR112018013292A2 - ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? - Google Patents
?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii?Info
- Publication number
- BR112018013292A2 BR112018013292A2 BR112018013292A BR112018013292A BR112018013292A2 BR 112018013292 A2 BR112018013292 A2 BR 112018013292A2 BR 112018013292 A BR112018013292 A BR 112018013292A BR 112018013292 A BR112018013292 A BR 112018013292A BR 112018013292 A2 BR112018013292 A2 BR 112018013292A2
- Authority
- BR
- Brazil
- Prior art keywords
- hallii
- preparation
- preparing
- butyric acid
- acid formation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/04—Preserving or maintaining viable microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
no presente documento, é descrito um método para cultivar e conservar o microrganismo probiótico do intestino eubacterium hallii. o método provê uma preparação de e. hallii que é adequada para administração ou ingestão em humanos e que provê altos rendimentos de biomassa de e. hallii. preferivelmente, o meio para cultivar e. hallii em altos rendimentos de biomassa compreende apenas componentes de qualidade alimentar, é isento de quaisquer fontes animais e/ou é kosher.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2016055 | 2015-12-31 | ||
PCT/NL2017/050001 WO2017116235A1 (en) | 2015-12-31 | 2017-01-02 | Method for culturing and preserving eubacterium hallii |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013292A2 true BR112018013292A2 (pt) | 2018-12-04 |
Family
ID=56990905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013292A BR112018013292A2 (pt) | 2015-12-31 | 2017-01-02 | ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? |
Country Status (12)
Country | Link |
---|---|
US (1) | US10806758B2 (pt) |
EP (1) | EP3397748B1 (pt) |
JP (1) | JP2019500035A (pt) |
KR (1) | KR20180091100A (pt) |
CN (1) | CN108699509A (pt) |
AU (1) | AU2017204717A1 (pt) |
BR (1) | BR112018013292A2 (pt) |
CA (1) | CA3008156C (pt) |
DK (1) | DK3397748T3 (pt) |
RU (1) | RU2737398C1 (pt) |
SG (1) | SG11201804847UA (pt) |
WO (1) | WO2017116235A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018013292A2 (pt) | 2015-12-31 | 2018-12-04 | Caelus Pharmaceuticals B V | ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? |
CA3014525A1 (en) | 2016-02-25 | 2017-08-31 | Caelus Pharmaceuticals B.V. | Compositions and methods for preventing and/or treating vitamin b12 deficiency |
WO2019157566A1 (en) * | 2018-02-16 | 2019-08-22 | St Vincent's Hospital (Melbourne) Limited | Compositions and methods for promoting gut health |
KR20220018964A (ko) * | 2019-04-22 | 2022-02-15 | 펜둘럼 테라퓨틱스 인코포레이티드 | 더 큰 내약성 및 연장된 저장 수명을 위한 미생물 조성물 및 방법 |
US20220395541A1 (en) * | 2019-12-20 | 2022-12-15 | Pendulum Therapeutics, Inc. | Methods and Compositions Comprising a Bacteria with Increased Viability and Faster Revivability |
FR3118059B1 (fr) * | 2020-12-18 | 2024-08-30 | Univ Bourgogne | Milieu de culture, procede de fabrication et procede de culture bacterienne |
CN115493919B (zh) * | 2022-11-21 | 2023-04-07 | 保定佳瑞源生物芯片有限公司 | 一种c肽和胰岛素检测试剂盒的校准品稀释液 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5443826A (en) | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
US5902578A (en) | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
US6224863B1 (en) | 1998-10-30 | 2001-05-01 | University Of South Carolina | Antibiotic composition from alcaligenes species and method for making and using the same |
EP1228769A1 (de) | 2001-02-02 | 2002-08-07 | Jörg-Peter Prof. Schür | Symbiontisches Regenerativum |
GB0307026D0 (en) * | 2003-03-27 | 2003-04-30 | Rowett Res Inst | Bacterial supplement |
US20080069861A1 (en) | 2006-09-19 | 2008-03-20 | National Starch And Chemical Investment Holding Corporation | Probiotic/Non-Probiotic Combinations |
WO2008076696A2 (en) | 2006-12-18 | 2008-06-26 | Washington University In St. Louis | The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder |
CN101496819A (zh) * | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | 真杆菌、梭菌制剂及其应用 |
US9603876B2 (en) | 2008-09-25 | 2017-03-28 | New York University | Compositions and methods for restoring gastrointestinal microbiota following antibiotic treatment |
WO2011043654A1 (en) | 2009-10-05 | 2011-04-14 | Aak Patent B.V. | Methods for diagnosing irritable bowel syndrome |
AU2011256017B2 (en) | 2010-05-18 | 2013-11-28 | Able Corporation | Method for inhibition of methane production |
WO2012142605A1 (en) | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
SG11201401811WA (en) * | 2011-08-30 | 2014-09-26 | Amc Amsterdam | Method for preventing and/or treating insulin resistance |
WO2014145958A2 (en) * | 2013-03-15 | 2014-09-18 | Seres Health, Inc. | Network-based microbial compositions and methods |
GB2551642B (en) * | 2014-10-31 | 2020-09-23 | Pendulum Therapeutics Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
BR112018013292A2 (pt) | 2015-12-31 | 2018-12-04 | Caelus Pharmaceuticals B V | ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? |
-
2017
- 2017-01-02 BR BR112018013292A patent/BR112018013292A2/pt not_active IP Right Cessation
- 2017-01-02 AU AU2017204717A patent/AU2017204717A1/en not_active Abandoned
- 2017-01-02 JP JP2018532242A patent/JP2019500035A/ja active Pending
- 2017-01-02 EP EP17701754.8A patent/EP3397748B1/en active Active
- 2017-01-02 US US16/060,902 patent/US10806758B2/en active Active
- 2017-01-02 DK DK17701754.8T patent/DK3397748T3/da active
- 2017-01-02 KR KR1020187021375A patent/KR20180091100A/ko unknown
- 2017-01-02 SG SG11201804847UA patent/SG11201804847UA/en unknown
- 2017-01-02 CA CA3008156A patent/CA3008156C/en active Active
- 2017-01-02 WO PCT/NL2017/050001 patent/WO2017116235A1/en active Application Filing
- 2017-01-02 CN CN201780005598.5A patent/CN108699509A/zh active Pending
- 2017-01-02 RU RU2018127184A patent/RU2737398C1/ru active
Also Published As
Publication number | Publication date |
---|---|
EP3397748B1 (en) | 2021-03-03 |
AU2017204717A1 (en) | 2018-08-02 |
US10806758B2 (en) | 2020-10-20 |
JP2019500035A (ja) | 2019-01-10 |
US20190151377A1 (en) | 2019-05-23 |
CN108699509A (zh) | 2018-10-23 |
KR20180091100A (ko) | 2018-08-14 |
DK3397748T3 (da) | 2021-05-10 |
RU2737398C1 (ru) | 2020-11-30 |
EP3397748A1 (en) | 2018-11-07 |
SG11201804847UA (en) | 2018-07-30 |
CA3008156C (en) | 2022-05-10 |
WO2017116235A1 (en) | 2017-07-06 |
CA3008156A1 (en) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013292A2 (pt) | ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii? | |
BR112018073750A2 (pt) | métodos para gerar proteínas de ligação ao antígeno contra um antígeno estranho de interesse e para produzir um animal não humano geneticamente modificado com tolerância reduzida de um antígeno estranho de interesse | |
CL2018001133A1 (es) | Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales | |
BR112016001026A2 (pt) | organismo geneticamente modificado | |
BR112015024330A2 (pt) | nova bactéria do ácido láctico, medicamento, alimento ou bebida, e ração que contenham a nova bactéria do ácido láctico | |
BR112017008905A2 (pt) | comidas para gato secas saborosas e métodos para preparação das mesmas | |
WO2019066577A3 (ko) | 짧은 사슬 지방산 생성 장내 세균 군집의 변화를 이용한 알코올성 간 질환의 진단 및 치료용 조성물 | |
BR112016024850A2 (pt) | composições e métodos para modulação da expressão 3 semelhante a antiopoietina | |
PH12018500090A1 (en) | Nutritional compositions and methods for promoting cognitive development | |
BR112016025792A2 (pt) | meios e processos para tratamento de cmv | |
MX2022011742A (es) | Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados. | |
BR112018009192A2 (pt) | composição de prebiótico e probiótico combinados | |
BR112018000236A2 (pt) | composições nutricionais e métodos para a promoção do desenvolvimento cognitivo | |
MY169265A (en) | Obesity animal model and methods for making and using thereof | |
BR112017008184A2 (pt) | composições e linhagem | |
BR112018003474A2 (pt) | bactérias lactobacillus fermentum que reduzem a concentração de acetaldeído | |
BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
BR112018009195A2 (pt) | fermentação | |
BR102014009838B8 (pt) | Método para produzir um l-aminoácido | |
AR103531A1 (es) | Composiciones de caldo y su uso como prebióticos | |
BR112016030294A8 (pt) | cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas | |
BR112017023636A2 (pt) | suplemento dietético | |
BR112017008776A2 (pt) | suplementos nutricionais que contêm um componente peptídico e seus usos | |
BR112017003558A2 (pt) | método de cultivo de um micro-organismo. | |
BR112017026005A2 (pt) | ?polipeptídeo, polinucleotídeo, micro-organismo do gênero escherichia, método de produção de o- acetil-homosserina e de l-metionina? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2651 DE 26-10-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |